MedPath

Capsaicin

Generic Name
Capsaicin
Brand Names
Capzasin Quick Relief, Capzasin-HP, Castiva Warming, Dendracin Neurodendraxcin, Lidopro, Medi-derm, Medi-derm With Lidocaine, Medrox, Qutenza, Rematex, Xoten-C, Zostrix
Drug Type
Small Molecule
Chemical Formula
C18H27NO3
CAS Number
404-86-4
Unique Ingredient Identifier
S07O44R1ZM

Overview

Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

Background

Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

Indication

The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.

Associated Conditions

  • Back Pain Lower Back
  • Back pain
  • Bursitis
  • Contusions
  • Inflammatory Reaction caused by Rheumatism
  • Muscle Cramps
  • Musculoskeletal Pain
  • Neuropathic Pain
  • Osteoarthritis (OA)
  • Pain caused by Rheumatism
  • Periarthritis
  • Soft Tissue Injury
  • Tendinitis
  • Acute nonspecific tenosynovitis
  • Articular inflammation

FDA Approved Products

Trubrexa
Manufacturer:Preferred Pharmaceuticals Inc.
Route:TRANSDERMAL
Strength:0.00025 g in 1 g
Approved: 2024/03/15
NDC:68788-8599
Releevia
Manufacturer:Patchwerx Labs, Inc
Route:TOPICAL
Strength:.0375 g in 100 g
Approved: 2014/11/15
NDC:69329-025
Medrox-Rx
Manufacturer:Pharmaceutica North America, Inc.
Route:TOPICAL
Strength:0.6 g in 120 g
Approved: 2011/10/27
NDC:45861-005
Trubrexa
Manufacturer:Asclemed USA, Inc.
Route:TRANSDERMAL
Strength:0.00025 g in 1 g
Approved: 2023/12/12
NDC:76420-644
Releevia MC
Manufacturer:Patchwerx Labs, Inc
Route:TOPICAL
Strength:.0375 g in 100 g
Approved: 2015/03/08
NDC:69329-030

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath